Evidence map›Paper›PMID 37426884›Full record

Trial reportGerman medical science : GMS e-journal2023

Effect of phthalocyanine oral and nasal antiseptic solutions on the infectivity of SARS-CoV-2 in patients with COVID-19: a randomized controlled trial.

Andréa Name Colado Simão, Nicole Perugini Stadtlober, Audrey Alesandra Stinghen Garcia Lonni, Luiza Mara Venâncio, Guilherme Lerner Trigo, Pedro Luis Candido de Souza Cassela, Thais Mastellini Sanches Silva, Maria De Fátima Oliveira Hirth Ruiz, Marcell Alysson Batisti Lozovoy, Zuleica Naomi Tano and 3 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in German medical science : GMS e-journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Andréa Name Colado SimãoResearch Laboratory in Applied Immunology, State University of Londrina, Brazil.
Nicole Perugini StadtloberResearch Laboratory in Applied Immunology, State University of Londrina, Brazil.
Audrey Alesandra Stinghen Garcia LonniDepartment of Pharmaceutical Sciences, State University of Londrina, Brazil.
Luiza Mara VenâncioResearch Laboratory in Applied Immunology, State University of Londrina, Brazil.
Guilherme Lerner TrigoResearch Laboratory in Applied Immunology, State University of Londrina, Brazil.
Pedro Luis Candido de Souza CasselaResearch Laboratory in Applied Immunology, State University of Londrina, Brazil.
Thais Mastellini Sanches SilvaResearch Laboratory in Applied Immunology, State University of Londrina, Brazil.
Maria De Fátima Oliveira Hirth RuizResearch Laboratory in Applied Immunology, State University of Londrina, Brazil.
Marcell Alysson Batisti LozovoyResearch Laboratory in Applied Immunology, State University of Londrina, Brazil.
Zuleica Naomi TanoResearch Laboratory in Applied Immunology, State University of Londrina, Brazil.
Bernardo da Fonseca OrcinaDepartment of Surgery, Stomatology, Pathology and Radiology, Bauru School of Dentistry, University of São Paulo, Bauru, Brazil.
Fabiano Vieira VilhenaTRIALS - Oral Health & Technologies, Bauru, Brazil.
Paulo Sérgio da Silva SantosDepartment of Surgery, Stomatology, Pathology and Radiology, Bauru School of Dentistry, University of São Paulo, Bauru, Brazil.
Universidade Estadual de Londrina · BRUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In individuals with coronavirus disease (COVID-19), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL) plays an important role in infectivity. Objectives: This study aimed to evaluate the reduction in the VL and infectivity induced by phthalocyanine mouthwash and nasal spray in patients with COVID-19. Methods: Patients with mild COVID-19 were recruited to participate in a triple-blinded randomized controlled trial. Participants were assigned to one of three groups: Group 1, non-active mouthwash and saline nasal spray (SNS); Group 2, phthalocyanine mouthwash and SNS; and Group 3 phthalocyanine mouthwash and phthalocyanine nasal spray. VL was assessed in nasopharyngeal and oropharyngeal swabs collected at the time of clinical diagnosis at baseline as well as 24 and 72 hours after starting the rinsing protocols. Findings: Forty-six participants were included in the analysis: 15, 16, and 15 in Groups 1, 2, and 3, respectively. After 72 hours, the reduction in VL was significantly higher in Group 3 (mean cycle threshold (Ct) decrease: 11.21) than in Group 1 (mean Ct decrease: 5.53). Additionally, only the mean VL in Group 3 was reduced to a non-contagious level after 72 hours. Main conclusions: Use of phthalocyanine mouthwash and nasal spray is effective at reducing SARS-CoV-2 infectivity.

Indexed as

Anti-Infective Agents, LocalCOVID-19HumansIsoindolesMouthwashesNasal SpraysSARS-CoV-2Anti-Infective Agents, LocalIsoindolesMouthwashesNasal SpraysphthalocyanineCOVID-19infectivitymouthwashesphthalocyanineSARS-CoV-2 infection

Identifiers

PMID37426884
PMCPMC10326526
OpenAlexW4383711361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.